Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15080468 | 1.00 | OPRD1 (0.77) | OPRD1 | |
| SCHEMBL4599124 | 0.93 | OPRD1 (0.76) | OPRD1 | |
| SCHEMBL6525400 | 0.88 | OPRD1 (0.61) | OPRD1 | |
| SCHEMBL14094906 | 0.87 | OPRD1 (0.75) | OPRD1 | |
| SCHEMBL12016532 | 0.87 | OPRD1 (0.77) | OPRD1 | |
| SCHEMBL5146349 | 0.87 | OPRD1 (0.77) | OPRD1 | |
| SCHEMBL3579696 | 0.87 | OPRD1 (1.00) | OPRD1 | |
| SCHEMBL3579700 | 0.87 | OPRD1 (1.00) | OPRD1 | |
| SCHEMBL8930484 | 0.87 | OPRD1 (1.00) | OPRD1 | |
| SCHEMBL29406897 | 0.87 | OPRD1 (1.00) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501513-B1 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | VERSI GROUP LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476280-B2 | Modulate contraction, relaxation of muscles | VERSI GROUP, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| EP-1501513-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | Ardent Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | VERSI GROUP, LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003094853-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.